PATENT CLAIM ANALYSIS

Application Number: 15919678
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["546", "112000"]

Abstract:
The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.

Claim (Index 7):
A method of enhancing motility of the gastrointestinal tract in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide, wherein a single crystal of the sulfate salt, analyzed at a temperature of \u2212153\u00b11\u00b0 C., is characterized by an orthorhombic unit cell with dimensions a=6.824 \u212b, b=16.228 \u212b, c=24.202 \u212b, \u03b1=\u03b2=\u03b3=90\u00b0, cell volume (V) of 2680.0 \u212b 3 , and a space group of P2 1 2 1 2 1 (#19).

Metadata:
- Claim Count in Document: 17.0
- Percentile: 90.0
- Lexical Diversity: 1.43396
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13081162', '12072534', '13550781', '13965691', '14333003']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8618510242592093
- 35 USC 102 Novelty (BERT): 0.6693792024617963
- Combined Prediction Score: 0.842603842079468
- Mean Citation Score: 693.9603860000003
- Max Citation Score: 700.8162
- Similarity Product: 643.5698569770456

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test